Skip to main content
. 2023 Jan 26;14:1120308. doi: 10.3389/fphys.2023.1120308

FIGURE 7.

FIGURE 7

Treatment of the CKD-MBD using the antibody to sclerostin increases VSMC Wnt activity and osteoblastic transdifferentiation, stimulating vascular calcification, but blocking systemic and skeletal sclerostin effects, thus stimulating bone formation. This would produce expected efficacy in skeletal outcomes but worsen cardiovascular disease.